197 related articles for article (PubMed ID: 21395551)
1. Role of the renin-angiotensin system in gynecologic cancers.
Ino K; Shibata K; Yamamoto E; Kajiyama H; Nawa A; Mabuchi Y; Yagi S; Minami S; Tanizaki Y; Kobayashi A; Kikkawa F
Curr Cancer Drug Targets; 2011 May; 11(4):405-11. PubMed ID: 21395551
[TBL] [Abstract][Full Text] [Related]
2. Role of the RAS in pancreatic cancer.
Lau ST; Leung PS
Curr Cancer Drug Targets; 2011 May; 11(4):412-20. PubMed ID: 21395550
[TBL] [Abstract][Full Text] [Related]
3. Manipulating the angiotensin system--new approaches to the treatment of solid tumours.
Ino K; Shibata K; Kajiyama H; Nawa A; Nomura S; Kikkawa F
Expert Opin Biol Ther; 2006 Mar; 6(3):243-55. PubMed ID: 16503734
[TBL] [Abstract][Full Text] [Related]
4. Engagement of renin-angiotensin system in prostate cancer.
Uemura H; Hoshino K; Kubota Y
Curr Cancer Drug Targets; 2011 May; 11(4):442-50. PubMed ID: 21395553
[TBL] [Abstract][Full Text] [Related]
5. The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis.
Ishikane S; Takahashi-Yanaga F
Biochem Pharmacol; 2018 May; 151():96-103. PubMed ID: 29534876
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II promotes the progression of human gastric cancer.
Huang MM; Guo AB; Sun JF; Chen XL; Yin ZY
Mol Med Rep; 2014 Mar; 9(3):1056-60. PubMed ID: 24424956
[TBL] [Abstract][Full Text] [Related]
7. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Coulson R; Liew SH; Connelly AA; Yee NS; Deb S; Kumar B; Vargas AC; O'Toole SA; Parslow AC; Poh A; Putoczki T; Morrow RJ; Alorro M; Lazarus KA; Yeap EFW; Walton KL; Harrison CA; Hannan NJ; George AJ; Clyne CD; Ernst M; Allen AM; Chand AL
Oncotarget; 2017 Mar; 8(12):18640-18656. PubMed ID: 28416734
[TBL] [Abstract][Full Text] [Related]
8. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Suganuma T; Ino K; Shibata K; Kajiyama H; Nagasaka T; Mizutani S; Kikkawa F
Clin Cancer Res; 2005 Apr; 11(7):2686-94. PubMed ID: 15814650
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling.
Du N; Feng J; Hu LJ; Sun X; Sun HB; Zhao Y; Yang YP; Ren H
Oncol Rep; 2012 Jun; 27(6):1893-903. PubMed ID: 22426690
[TBL] [Abstract][Full Text] [Related]
10. Renin angiotensin system blockade ameliorates lead nephropathy.
Ng HY; Tain YL; Lee YT; Hsu CY; Chiou TT; Huang PC; Lee CT
Biochem Biophys Res Commun; 2013 Aug; 438(2):359-63. PubMed ID: 23896603
[TBL] [Abstract][Full Text] [Related]
11. The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review.
Almeida-Santos AF; Kangussu LM; Campagnole-Santos MJ
Protein Pept Lett; 2017 Nov; 24(9):841-853. PubMed ID: 28828974
[TBL] [Abstract][Full Text] [Related]
12. Blockade of the renin-angiotensin system ameliorates apelin production in 3T3-L1 adipocytes.
Hung WW; Hsieh TJ; Lin T; Chou PC; Hsiao PJ; Lin KD; Shin SJ
Cardiovasc Drugs Ther; 2011 Feb; 25(1):3-12. PubMed ID: 21161354
[TBL] [Abstract][Full Text] [Related]
13. Regulation of colorectal cancer cell epithelial to mesenchymal transition by the renin angiotensin system.
Nguyen L; Ager EI; Neo J; Christophi C
J Gastroenterol Hepatol; 2016 Oct; 31(10):1773-1782. PubMed ID: 26849969
[TBL] [Abstract][Full Text] [Related]
14. Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition.
Sullivan JC
Am J Physiol Regul Integr Comp Physiol; 2008 Apr; 294(4):R1220-6. PubMed ID: 18287217
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway.
Zhao Y; Chen X; Cai L; Yang Y; Sui G; Fu S
J Cell Physiol; 2010 Oct; 225(1):168-73. PubMed ID: 20458733
[TBL] [Abstract][Full Text] [Related]
16. The Renin-Angiotensin System and the Cerebrovascular Diseases: Experimental and Clinical Evidence.
Kangussu LM; Marzano LAS; Souza CF; Dantas CC; Miranda AS; Simões E Silva AC
Protein Pept Lett; 2020; 27(6):463-475. PubMed ID: 31849284
[TBL] [Abstract][Full Text] [Related]
17. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
Krum H; Gilbert RE
J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
[TBL] [Abstract][Full Text] [Related]
18. [Cancer and renin-angiotensin system].
Uemura H; Kubota Y
Nihon Rinsho; 2012 Sep; 70(9):1530-5. PubMed ID: 23012799
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS.
Patel VB; Clarke N; Wang Z; Fan D; Parajuli N; Basu R; Putko B; Kassiri Z; Turner AJ; Oudit GY
J Mol Cell Cardiol; 2014 Jan; 66():167-76. PubMed ID: 24332999
[TBL] [Abstract][Full Text] [Related]
20. Plasma and tissue concentrations of proangiotensin-12 in rats treated with inhibitors of the renin-angiotensin system.
Nagata S; Kato J; Kuwasako K; Asami M; Kitamura K
Hypertens Res; 2012 Feb; 35(2):234-8. PubMed ID: 21993212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
